NasdaqGS - Nasdaq Real Time Price USD

BioAge Labs, Inc. (BIOA)

4.0200

+0.1500

+(3.88%)

At close: April 21 at 4:00:01 PM EDT

3.9115

-0.11

(-2.70%)

After hours: April 21 at 7:38:39 PM EDT

BioAge Labs, Inc. (BIOA): A Bull Case Theory

We came across a bullish thesis on BioAge Labs, Inc. (BIOA) on Substack by Ragnarok Research. In this article, we will summarize the bulls’ thesis on BIOA. BioAge Labs, Inc. (BIOA)’s share was trading at $3.87 as of April 17th. BioAge Labs (BIOA) represents a classic “cigarette butt” investment—an overlooked and beaten-down company that still has a […]

Insider Monkey 10 hours ago

BIOA
+3.88%
Several Insiders Invested In BioAge Labs Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. 26 days ago

BIOA
+3.88%
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic disea

GlobeNewswire last month

BIOA
+3.88%
BioArctic receives Orphan Drug Designation for exidavnemab the US

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need.

PR Newswire last month

BIOA
+3.88%
BRCTF
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3–5, 2025, at the Boston Marriott Copley Place in B

GlobeNewswire last month

BIOA
+3.88%
BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.

BioPharma Dive 2 months ago

BIOA
+3.88%
AKRO

VNDA
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

Advancement of next-generation APJ agonists with discontinuation of azelaprag Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, including a target identification collaboration with Novartis and a newly announced antibody therapeutics development collaboration with Lilly ExploR&D RICHMOND, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("B

GlobeNewswire 2 months ago

BIOA
+3.88%
After an obesity stumble, BioAge reconnects with its longevity pipeline

The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.

Pharma Voice 2 months ago

BIOA
+3.88%
NVS
BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge Labs, Inc. (BIOA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 3 months ago

BIOA
+3.88%
BioAge and Novartis seek drug targets for ageing-related diseases

BioAge will receive an upfront payment and research funding of up to $20m.

Pharmaceutical Technology 3 months ago

BIOA
+3.88%
NVS
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront payments and research funding; BioAge may receive up to $530M in future long-term research, development, and commercial milestones RICHMOND, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biopharmaceutical c

GlobeNewswire 4 months ago

BIOA
+3.88%
3 closely watched drugs that failed in the clinic

How recent setbacks and scattered successes could impact various sectors of the industry.

Pharma Voice 4 months ago

BIOA
+3.88%
ABBV
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.

Clinical Trials Arena 4 months ago

BIOA
+3.88%
LLY
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

On Friday, BioAge Labs Inc. (NASDAQ:BIOA) announced that it will discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate, azelaprag. STRIDES was being conducted in collaboration with Eli Lilly And Co’s (NYSE:LLY) Chorus clinical development organization. Top-line results were anticipated in the third quarter of 2025. The move follows after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. STRIDES is a Phase

Benzinga 4 months ago

BIOA
+3.88%
LLY
BioAge shares tumble after decision to halt obesity drug study

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following safety concerns.

BioPharma Dive 4 months ago

BIOA
+3.88%
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025 RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Na

GlobeNewswire 4 months ago

BIOA
+3.88%
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Goldman Sachs Second Annual “Year-Ahead” Catalyst Clinic on Thursday, December 19, 2024, 11–12 PM EST. To access the live webcast of the virtual presentation, register here. Replays of the web

GlobeNewswire 4 months ago

BIOA
+3.88%
Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

We recently published a list of 10 Best All-Time Low Stocks To Buy Right Now. In this article, we are going to take a look at where BioAge Labs, Inc. (NASDAQ:BIOA) stands against other best all-time low stocks to buy right now. With November coming to a close, while markets are focused on the future […]

Insider Monkey 4 months ago

BIOA
+3.88%
BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference (New York, December 3-5, 2024): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participa

GlobeNewswire 4 months ago

BIOA
+3.88%
BioAge Labs Reports Strong Q3 2024 Achievements

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors. BioAge Labs, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases, such as obesity, by targeting the biology of human aging. The company recently reported its third-quarter 2024 financial results, highlighting significant milestones achieved during the period. In the third quarter of 2024, BioAge Labs i

TipRanks 5 months ago

BIOA
+3.88%

Performance Overview

Return	BIOA	S&P 500 (^GSPC)
YTD	-30.57%	-12.30%
1-Year	-82.13%	+3.84%
3-Year	-82.13%	+17.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA): A Bull Case Theory

Several Insiders Invested In BioAge Labs Flagging Positive News

BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

BioArctic receives Orphan Drug Designation for exidavnemab the US

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs

After an obesity stumble, BioAge reconnects with its longevity pipeline

BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

BioAge and Novartis seek drug targets for ageing-related diseases

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

3 closely watched drugs that failed in the clinic

BioAge halts ongoing Phase II trial of obesity drug due to liver concerns

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns

BioAge shares tumble after decision to halt obesity drug study

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now?

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Strong Q3 2024 Achievements

Performance Overview